Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere	Unresectable Hepatocellular Carcinoma	Active, not recruiting	Phase 3	2026-06-09		NCT06900543

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chengdu New Radiomedicine Technology Co. LTD.	3

19 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fujian Cancer Hospital	Fuzhou	China	55
Henan Cancer Hospital	Zhengzhou	China	98
Mengchao Hepatobiliary Hospital of Fujian Medical University	Fuzhou	China	9
The Affiliated Hospital of Southwest Medical University	Luzhou	China	11
The First Affiliated Hospital of Fujian Medical University	Fuzhou	China	21
The First Affiliated Hospital of Jinan University	Guangzhou	China	9
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	103
The first affiliated hospital, Zhejiang university school of medicine	Hangzhou	China	27
The First Hospital Affiliated to the Army Medical University	Chongqing	China	1
The First Hospital of China Medical University	Shenyang	China	42
The Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	China	14
The Third Affiliated Hospital of Sun Yat-sen University	Guangzhou	China	17
Tianjin Cancer Hospital Airport Hospital	Tianjin	China	6
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	54
West China Hospital	Chengdu	China	21
Xi'an International Medical Center Hospital	Xi’an	China	1
Zhongda Hospital Southeast University	Nanjing	China	25
Zhongnan Hospital of Wuhan University	Wuhan	China	34
ZhongShan Hospital Fudan University	Shanghai	China	22